Last reviewed 2026-04-23 · How we verify

AVANZ Salsola

ALK-Abelló A/S · Phase 2 active Biologic

AVANZ Salsola is a Biologic drug developed by ALK-Abelló A/S. It is currently in Phase 2 development.

At a glance

Generic name	AVANZ Salsola
Sponsor	ALK-Abelló A/S
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

An Open Trial to Assess the Tolerability of AVANZ® Salsola Immunotherapy (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AVANZ Salsola CI brief — competitive landscape report
AVANZ Salsola updates RSS · CI watch RSS
ALK-Abelló A/S portfolio CI

Frequently asked questions about AVANZ Salsola

What is AVANZ Salsola?

AVANZ Salsola is a Biologic drug developed by ALK-Abelló A/S.

Who makes AVANZ Salsola?

AVANZ Salsola is developed by ALK-Abelló A/S (see full ALK-Abelló A/S pipeline at /company/alk-abell-a-s).

What development phase is AVANZ Salsola in?

AVANZ Salsola is in Phase 2.

Manufacturer: ALK-Abelló A/S — full pipeline
Compare: AVANZ Salsola vs similar drugs
Pricing: AVANZ Salsola cost, discount & access